Understanding Gastroparesis Risk with Ozempic in California

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Targeted Exposure Awareness

If you or a loved one has been taking Ozempic and developed persistent nausea, vomiting, or abdominal pain, you may be concerned about gastroparesis. Decades of pharmacovigilance research have established that delayed gastric emptying is a recognized adverse effect of GLP-1 receptor agonists. This page explains the monitoring recommendations and what California patients should know about this condition.

Find Out If You Qualify for Compensation →

Bridging General Knowledge to Specific Risk: Ozempic and Gastroparesis

Building on the legacy of general health information, this section bridges to the specific medical and legal context of Ozempic-associated gastroparesis. Ozempic, a glucagon-like peptide-1 (GLP-1) receptor agonist, is prescribed for glycemic control in type 2 diabetes. However, its use has been associated with a range of gastrointestinal adverse reactions, including a condition known as gastroparesis—a disorder characterized by delayed gastric emptying without mechanical obstruction. This narrative examines the clinical presentation of gastroparesis, the pharmacological link to Ozempic, and the legal considerations for affected patients in California, particularly regarding the statute of limitations. Gastroparesis presents with symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. The condition can lead to malnutrition, dehydration, and severe complications like bezoar formation.

Clinical Evidence Linking Ozempic to Gastroparesis

In the context of Ozempic, clinical trial data show that gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: placebo 15.3%, Ozempic 0.5 mg 32.7%, and Ozempic 1 mg 36.4% (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additionally, specific gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (1.9% placebo, 3.5% 0.5 mg, 2.7% 1 mg), gastroesophageal reflux disease (0% placebo, 1.9% 0.5 mg, 1.5% 1 mg), and gastritis (0.8% placebo, 0.8% 0.5 mg, 0.4% 1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal side effects, which may contribute to gastroparesis. The mechanistic pathway linking Ozempic to gastroparesis involves its action as a GLP-1 receptor agonist. GLP-1 slows gastric emptying by inhibiting antral contractions and stimulating pyloric tone, a physiological effect that can become pathological in susceptible individuals. Postmarketing reports have highlighted the risk of pulmonary aspiration in patients undergoing elective surgeries or procedures requiring general anesthesia or deep sedation, due to residual gastric contents despite adherence to preoperative fasting recommendations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). This underscores the potential for severe delayed gastric emptying, a hallmark of gastroparesis. The available data are insufficient to inform recommendations to mitigate the risk of pulmonary aspiration, including whether modifying preoperative fasting or temporarily discontinuing Ozempic could reduce the incidence of retained gastric contents (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). Patients are instructed to inform healthcare providers prior to any planned surgeries or procedures if they are taking Ozempic (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98).

Risk Context and Adequacy of Warnings

From a risk perspective, the adequacy of warnings regarding Ozempic and gastroparesis is a critical issue. The prescribing information for Ozempic lists gastrointestinal adverse reactions but does not explicitly mention gastroparesis as a specific warning. The label notes that more patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions compared to placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the absence of a direct warning for gastroparesis may leave patients unaware of the potential for this serious condition. For affected patients in California, attorney-related considerations are paramount. The statute of limitations for personal injury claims in California is generally two years from the date of injury or discovery of the injury. For product liability claims involving Ozempic, the timeline between exposure and documented harm is crucial. Patients who develop gastroparesis after starting Ozempic must establish when the injury was or should have been discovered. This can be challenging, as symptoms may develop gradually and be attributed to other causes. Legal counsel can help navigate these complexities, including gathering medical records to demonstrate the temporal relationship between Ozempic use and the onset of gastroparesis.

Conclusion and Legal Considerations

In summary, the evidence indicates a plausible link between Ozempic and gastroparesis, supported by clinical trial data showing increased gastrointestinal adverse reactions and postmarketing reports of delayed gastric emptying. The adequacy of warnings remains a concern, as the label does not specifically address gastroparesis. For California patients, the statute of limitations requires prompt legal action after discovery of harm. Consulting an attorney experienced in pharmaceutical litigation is advisable to assess individual cases and ensure timely filing.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in California?

In California, the statute of limitations for personal injury claims, including product liability cases involving Ozempic, is generally two years from the date of injury or from the date the injury was discovered or should have been discovered. For gastroparesis, which may develop gradually, it is crucial to consult an attorney promptly to determine the exact deadline based on your specific circumstances.

Does the Ozempic label warn about gastroparesis?

The prescribing information for Ozempic lists gastrointestinal adverse reactions such as nausea, vomiting, and diarrhea, but does not explicitly mention gastroparesis as a specific warning. This lack of a direct warning may affect legal claims regarding inadequate warnings. Patients should review the label and discuss any concerns with their healthcare provider.

What evidence links Ozempic to gastroparesis?

Clinical trial data show a dose-dependent increase in gastrointestinal adverse reactions with Ozempic compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Postmarketing reports also highlight risks of delayed gastric emptying and pulmonary aspiration (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). These findings support a plausible link between Ozempic and gastroparesis.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.